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Abstract
Context—Data regarding the association between subclinical hypothyroidism and cardiovascular
disease outcomes are conflicting among large prospective cohort studies. This might reflect
differences in participants’ age, sex, thyroid-stimulating hormone (TSH) levels, or preexisting
cardiovascular disease.
Objective—To assess the risks of coronary heart disease (CHD) and total mortality for adults
with subclinical hypothyroidism.
Data Sources and Study Selection—The databases of MEDLINE and EMBASE (1950 to
May 31, 2010) were searched without language restrictions for prospective cohort studies with
baseline thyroid function and subsequent CHD events, CHD mortality, and total mortality. The
reference lists of retrieved articles also were searched.
Data Extraction—Individual data on 55 287 participants with 542 494 person-years of follow-
up between 1972 and 2007 were supplied from 11 prospective cohorts in the United States,
Europe, Australia, Brazil, and Japan. The risk of CHD events was examined in 25 977 participants
from 7 cohorts with available data. Euthyroidism was defined as a TSH level of 0.50 to 4.49 mIU/
L. Subclinical hypothyroidism was defined as a TSH level of 4.5 to 19.9 mIU/L with normal
thyroxine concentrations.
Results—Among 55 287 adults, 3450 had subclinical hypothyroidism (6.2%) and 51 837 had
euthyroidism. During follow-up, 9664 participants died (2168 of CHD), and 4470 participants had
CHD events (among 7 studies). The risk of CHD events and CHD mortality increased with higher
TSH concentrations. In age- and sex-adjusted analyses, the hazard ratio (HR) for CHD events was
1.00 (95% confidence interval [CI], 0.86–1.18) for a TSH level of 4.5 to 6.9 mIU/L (20.3 vs
20.3/1000 person-years for participants with euthyroidism), 1.17 (95% CI, 0.96–1.43) for a TSH
level of 7.0 to 9.9 mIU/L (23.8/1000 person-years), and 1.89 (95% CI, 1.28–2.80) for a TSH level
of 10 to 19.9 mIU/L (n=70 events/235; 38.4/1000 person-years; P<.001 for trend). The
corresponding HRs for CHD mortality were 1.09 (95% CI, 0.91–1.30; 5.3 vs 4.9/1000 person-
years for participants with euthyroidism), 1.42 (95% CI, 1.03–1.95; 6.9/1000 person-years), and
1.58 (95% CI, 1.10–2.27, n=28 deaths/333; 7.7/1000 person-years; P=.005 for trend). Total
mortality was not increased among participants with subclinical hypothyroidism. Results were
similar after further adjustment for traditional cardiovascular risk factors. Risks did not
significantly differ by age, sex, or preexisting cardiovascular disease.
Conclusions—Subclinical hypothyroidism is associated with an increased risk of CHD events
and CHD mortality in those with higher TSH levels, particularly in those with a TSH
concentration of 10 mIU/L or greater.
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Controversy persists on the indications for screening and threshold levels of thyroid-
stimulating hormone (TSH) for treatment of subclinical hypothyroidism,1–3 defined as
elevated serum TSH levels with normal thyroxine (T4) concentrations. Because subclinical
hypothyroidism has been associated with hypercholesterolemia4 and atherosclerosis,5
screening and treatment have been advocated to prevent cardiovascular disease.3 However,
data on the associations with coronary heart disease (CHD) events and mortality are
conflicting among several large prospective cohorts.6–9 Three recent study-level meta-
analyses10–12 found modestly increased risks for CHD and mortality, but with heterogeneity
among individual studies that used different TSH cutoffs, different confounding factors for
adjustment, and varying CHD definitions.10 Part of the heterogeneity might also be related
to differences in participants’ age, sex, or severity of subclinical hypothyroidism (as
measured by TSH level).4 One cohort study suggested particularly high risk in participants
with subclinical hypothyroidism and preexisting cardiovascular disease.8
Analysis of individual participant data from large cohort studies may reconcile these
conflicting data and define the influence of age, TSH levels, and preexisting cardiovascular
disease. Individual participant data analysis is considered the best way for synthesizing
evidence across several studies because it is not subject to potential bias from study-level
meta-analyses (ecological fallacy)13 and allows performance of time-to-event analyses.14
To clarify the cardiovascular risk of subclinical hypothyroidism, we formed the Thyroid
Studies Collaboration and conducted an individual participant data analysis of subclinical
hypothyroidism and CHD outcomes.
METHODS
Identification of potential studies was based on protocols developed for our study-level
meta-analysis of prospective cohort studies.10 Briefly, we conducted a systematic literature
search of articles in all languages on the association between subclinical thyroid dysfunction
and CHD or mortality (cardiovascular and total) published from 1950 to May 31, 2010, in
the MEDLINE and EMBASE databases and searched bibliographies of key articles (details
are available in the eMethods at http://www.jama.com). To maximize the quality and
comparability of the studies, we formulated general inclusion criteria a priori. We included
only full-text, published longitudinal cohort studies that (1) measured thyroid function with
both serum TSH level and thyroxine (T4) level at baseline in adults, (2) followed up
participants systematically over time, (3) assessed CHD events and/or mortality, and (4) had
a comparison group with euthyroidism. We excluded studies that only examined persons
taking antithyroid medications, thyroxine replacement or amiodarone, or with overt
hypothyroidism (defined as low T4 and elevated TSH concentrations). Possible studies for
inclusion were independently assessed for suitability by 2 of the authors (N.R., J.G.) and any
disagreement was resolved by discussion with a third author (D.C.B). The agreement
between the 2 reviewers was 99.9% for the first screen (titles and abstracts, κ=0.98) and
100% for the full-text screen (κ=1.00).
Investigators from each eligible study were invited to join the Thyroid Studies
Collaboration. We collected detailed information about prespecified outcomes and potential
confounding variables for each participant. Requested data included individual demographic
characteristics, baseline thyroid function(TSH and T4 levels), baseline cardiovascular risk
factors (eg, low- and high-density lipoprotein cholesterol level, diabetes, blood pressure,
cigarette smoking), prevalent cardiovascular disease, medication use at baseline (thyroid
medication, lipid-lowering and antihypertensive drugs), and outcome data.
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To maximize the comparability of the studies, we used a common definition of subclinical
hypothyroidism. Based on expert reviews1,2 and definitions used in the Cardiovascular
Health Study,6,15 we defined subclinical hypothyroidism as a serum TSH level of 4.5 mIU/L
or greater to less than 20 mIU/L, with a normal T4 concentration; and euthyroidism was
defined as a serum TSH level of 0.5 mIU/L or greater and less than 4.5 mIU/L. Because the
Whickham Survey used a first-generation TSH radioimmunoassay, which gives higher
measured TSH values than current assays,16 a TSH range of 6.0 mIU/L or greater to less
than 21.5 mIU/L was used for this individual participant data analyses, as in the original and
recent analysis of this study.17,18 In that study, a serum TSH level of 6.0 mIU/L
corresponded to the 97.5th percentile of the group with negative thyroid antibodies,18 which
is close to the modern level of 4.5 mIU/L for the current generation of assays. For T4 level,
we used site- and method-dependent specific cutoffs (eTable at http://www.jama.com)
because T4 measurements show greater intermethod variation than do sensitive TSH assays.
The Whickham Survey measured total T4 level.18 Participants with abnormal T4 values,
results suggestive of nonthyroidal illness (low TSH and FT4 levels) or low TSH level (<0.5
mIU/L) were excluded (n=3023). Some studies had participants with missing T4 values
(eTable); we considered participants with a TSH level of 4.5 mIU/L to 19.9 mIU/L and a
missing T4 level as having subclinical hypothyroidism because most adults with this degree
of TSH elevation have subclinical and not overt hypothyroidism.19 We performed a
sensitivity analysis excluding those with a missing T4 level.
Outcome measures were CHD events, CHD mortality, and total mortality. To limit outcome
heterogeneity observed with previous study-level meta-analyses,10–12 we used more
homogeneous outcome definitions. Similar to the current Framingham risk score,20 we
limited cardiovascular mortality to CHD mortality or sudden death (eTable). A CHD event
was defined as nonfatal myocardial infarction or CHD death (equivalent to hard events in
the Framingham risk score20) and hospitalization for angina or coronary revascularization
(coronary artery bypass grafting or angioplasty).6 We performed a sensitivity analysis with
hard events only.
Using previously described criteria10 and new information from study authors, we
systematically evaluated the following key indicators of study quality13: methods of
outcome adjudication and ascertainment, accounting for confounders, and completeness of
follow-up ascertainment. Two reviewers (N.R., J.G.) rated all studies for quality.
We used separate Cox proportional hazard models to assess the associations of subclinical
hypothyroidism with CHD events and mortality for each cohort (SAS version 9.2, SAS
Institute Inc, Cary, North Carolina). Pooled estimates for each outcome were calculated
using random-effects models, based on the variance model according to DerSimonian and
Laird,21 as recommended14,22 and published in recent 2-stage individual participant data
analyses.23 Results were summarized using forest plots (Review Manager version 5.0.24,
Nordic Cochrane Centre, Copenhagen, Denmark). The research authors of 1 study with 14
CHD outcomes5,10 declined to participate; as recommended,24 we included the published
summary estimate from that study in the random-effects models in a sensitivity analysis. To
assess heterogeneity across studies, we used the I2 statistic, which describes the total
variation across studies attributable to heterogeneity rather than chance (I2>50% indicating
at least moderate statistical heterogeneity).25
Primary analyses were adjusted for age and sex, and then for traditional cardiovascular risk
factors (systolic blood pressure, smoking, total cholesterol, diabetes) that were available in
all cohorts (except for the Birmingham Study,26 which was excluded from this analysis). We
considered the age- and sex-adjusted model as the primary analysis because some traditional
Rodondi et al. Page 4
JAMA. Author manuscript; available in PMC 2014 February 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
risk factors are potential mediators of the relationship between subclinical hypothyroidism
and CHD.4
To explore sources of heterogeneity, we performed several predefined subgroup and
sensitivity analyses. We conducted stratified analyses by age, sex, race, TSH concentrations,
and preexisting cardiovascular disease. Based on expert reviews1,2 and previous studies,7,15
subclinical hypothyroidism was stratified according to the following TSH concentration
categories: 4.5–6.9 mIU/L (mild elevation), 7.0–9.9 mIU/L (moderate elevation), and 10.0–
19.9 mIU/L(marked elevation). In the study-specific analyses stratified by age or TSH level,
some strata had participants without either CHD deaths or CHD events (for 1 study27). For
these study-specific analyses, we used penalized likelihood methods28 to obtain hazard
ratios (HRs) and confidence intervals (CIs). As done in previous studies,7,27,29 after
including all participants in the primary analyses, we performed sensitivity analyses
excluding participants who had thyroid hormone use at baseline and during follow-up. To
calculate age- and sex-adjusted rates per 1000 person-years, we first fit Poisson models30 to
the pooled data, then standardized the fitted rate in the euthyroidism group to the overall age
and sex distribution of the pooled sample. Finally, to obtain rates in the TSH groups
consistent with the meta-analytic results, we multiplied the standardized rates in the
euthyroidism group by the summary meta-analytic HRs. We checked the proportional
hazard assumption using graphical methods and Schoenfeld tests (all P>.05). We used the
Egger test31 and age- and sex-adjusted funnel plots to assess for publication bias.
RESULTS
Among 4440 reports identified, 12 prospective studies met eligibility criteria (eFigure at
http://www.jama.com) and 11 prospective cohorts in the United States, Europe, Australia,
Brazil, and Japan agreed to provide individual participant data (Table 1). The final sample
included 55 287 adults comprising 3450 with subclinical hypothyroidism (6.2%) and 51 837
with euthyroidism. Zero to 8.3% of participants reported thyroid hormone use at baseline
(all excluded in 5 studies) and 0% to 12.6% reported thyroid hormone use during follow-up.
The median follow-up ranged from 2.5 to 20 years, with total follow-up of 542 494 person-
years.
All 11 cohort studies reported total and CHD deaths, and 7 studies also reported CHD events
among 25 977 participants. For the quality of individual studies, all studies reported
outcome adjudication without knowledge of thyroid status; 4 of 7 studies reporting CHD
events used formal adjudication procedures6–8,27; and 4 of 11 studies reporting CHD deaths
mainly used death certificates.26,33–35 All studies had 5% or less loss to follow-up.
During follow-up, 9664 participants died (2168 of CHD) and 4470 participants had CHD
events (among 7 studies). In age- and sex-adjusted analyses, the overall HR for participants
with subclinical hypothyroidism compared with euthyroidism was 1.18 (95% CI, 0.99–1.42)
for CHD events (24.0 vs 20.3/1000 person-years for participants with euthyroidism), 1.14
(95% CI, 0.99–1.32) for CHD mortality (5.5 vs 4.9/1000 person-years), and 1.09 (95% CI,
0.96–1.24) for total mortality (23.1 vs 21.1/1000 person-years; Figure 1). We found
heterogeneity across studies for CHD events (I2=59%) and total mortality (I2=66%), but not
for CHD mortality (I2=0%). We subsequently examined whether heterogeneity was related
to differences in risks by degree of subclinical hypothyroidism and age. The risk of CHD
events (P<.001 for trend) and CHD death (P=.005 for trend) increased with higher TSH
level, but not for total mortality (Figure 2). In stratified analyses, participants with TSH
levels of 10 mIU/L or greater had significantly increased risk of CHD events (HR, 1.89
[95% CI, 1.28–2.80]; n=70 events/235; 38.4 vs 20.3/1000 person-years for participants with
euthyroidism) and CHD mortality (HR, 1.58 [95% CI, 1.10–2.27]; n = 28 deaths/333; 7.7 vs
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4.9/1000 person-years) compared with participants with euthyroidism. The risk for CHD
associated with subclinical hypothyroidism appeared to be somewhat higher in younger
participants, but the number of outcomes in the younger age group was small, and there was
no significant trend in CHD risk across age groups. Otherwise, the risk estimates for CHD
events, CHD mortality, and total mortality did not differ significantly according to age, sex,
race, or preexisting cardiovascular disease, except an increase in CHD events and CHD
mortality among white but not among nonwhite participants with subclinical
hypothyroidism (Table 2). All results were similar after further adjustment for traditional
cardiovascular risk factors.
Sensitivity analyses yielded similar results, with increased risks of CHD events and
mortality in those with TSH levels of 10 mIU/L or greater (Table 3). Risk estimates were
slightly higher for those with TSH levels of 10 mIU/L or greater after excluding those who
took thyroid medication during follow-up. Estimates were lower for subclinical
hypothyroidism overall after limiting the analyses to 4 studies with formal adjudication
procedures, but slightly higher for those with TSH levels of 10 mIU/L or greater. The effect
of increasing TSH level on CHD events did not significantly differ according to age (P=.87
for interaction). We found no evidence of publication bias, either with visual assessment of
age- and sex-adjusted funnel plots or with the Egger test for mortality data (P=.39 for CHD
mortality and P=.97 for total mortality) and little evidence of publication bias for CHD
events (P=.13 for CHD events).
COMMENT
In this analysis of 55 287 individual participants from 11 prospective cohort studies,
subclinical hypothyroidism was associated with an increased risk of CHD events and CHD
mortality in those with higher TSH levels. There was a significant trend of increased risk at
higher serum TSH concentrations, and the risk of both CHD mortality and CHD events was
significantly increased in participants with TSH levels of 10 mIU/L or greater. These
associations persisted after adjustment for traditional cardiovascular risk factors, and did not
significantly differ by age, sex, race, or preexisting cardiovascular disease. Compared with
participants with euthyroidism, the overall HR for CHD events with subclinical
hypothyroidism was 1.18 (95% CI, 0.99–1.42) and the overall HR for CHD mortality was
1.14 (95% CI, 0.99–1.32). Minimal TSH elevations were not associated with an increased
risk of CHD events and CHD mortality. Our results clarify the CHD risk of subgroups of
adults with subclinical hypothyroidism, which could not be adequately addressed in
previous study-level meta-analyses10–12 or in single cohort studies performed in more
limited age groups or without TSH stratification.6,7,26,27
These results are generally consistent with previous study-level meta-analyses showing
modest increased risks of CHD events and cardiovascular mortality associated with
subclinical hypothyroidism.10,11 However, these meta-analyses could not accurately explore
potential differences related to participant characteristics (eg, age, TSH concentrations)
because of potential bias without individual participant data analysis (ecological fallacy),13
and they also were limited by clinical heterogeneity,10,36 with individual studies using
varying TSH cutoffs, confounding factors for adjustment, and CHD definitions. Among 11
cohorts, only 2 studies previously reported results stratified by TSH level. One study9
reported an increased risk of CHD events in participants with a TSH level of 10.0 mIU/L or
greater (HR, 2.2; 95% CI, 1.2–4.2) and the other study7 reported an increased risk of
cardiovascular mortality (HR, 2.26; 95% CI, 0.54–9.45) but not CHD events (HR, 0.96;
95% CI, 0.35–2.61) over 4 years among adults aged 70 to 79 years with TSH levels of 10
mIU/L or greater. However, the HR for CHD events increased to 1.28 (95% CI, 0.68–2.39)
with extended follow-up to 8 years in the present data. In overall pooled data, we found
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statistical heterogeneity among individual study findings for CHD events (I2=59%), but not
for CHD death. Part of the heterogeneity might be related to different CHD risks across age,
race, and TSH subgroups.
Our individual participant data analysis found that the CHD outcomes in adults with
subclinical hypothyroidism did not differ significantly across age groups. For the specific
age group of 80 years or older, there was no significant increased risk of total mortality,
CHD mortality, or CHD events in contrast to a single previous study that found reduced
mortality associated with increasing TSH concentrations.27,37 Previous study-level meta-
analyses have found increased risks of CHD events and cardiovascular mortality associated
with subclinical hypothyroidism, particularly in studies with a mean age of younger than 65
years,10,11 but this was not confirmed by our individual participant data analysis. We found
some evidence for increased risks of CHD events and mortality in younger adults with
subclinical hypothyroidism, but there also were large 95% CIs without significant trend
across age groups (Figure 2). Moreover, the effect of increasing TSH level on CHD events
did not significantly differ according to age. In contrast to a previous study suggesting that
adults with subclinical hypothyroidism and preexisting cardiovascular disease might be at
particularly high cardiovascular risk,8 we found no significant effect of baseline preexisting
cardiovascular disease on outcomes.
The increased risk of CHD events associated with higher TSH levels in our study might be
related to the known effects of thyroid hormone on the heart and metabolism, consistent
with the concept that subclinical hypothyroidism is a milder form of overt
hypothyroidism.38,39 Increased systemic vascular resistance, arterial stiffness, altered
endothelial function, increased atherosclerosis, and altered coagulability have been reported
to be associated with subclinical hypothyroidism and may accelerate development of
CHD.4,39,40 The fact that adjustment for traditional cardiovascular risk factors did not alter
risks could favor this hypothesis. Other potential mechanisms include elevated cholesterol
level,4,39 although adjustment for cholesterol level did not remove the associations in our
data. Adults with higher TSH concentrations also are more likely to develop overt
hypothyroidism,41 and it is possible that this progression explains the association with
subclinical hypothyroidism. Alternative explanations for the observed results are bias in the
selection of included studies, bias and quality problems in the original studies, publication
bias, and unmeasured confounders.42 Sensitivity analyses pooling higher-quality studies
yielded similar results. Whereas one randomized controlled trial has shown benefits with
thyroxine treatment of subclinical hypothyroidism on intima-media thickness40 and another
has shown benefits with thyroxine treatment of subclinical hypothyroidism on brachial
artery endothelial function,43 the potential causal relationship can only be proven by
randomized controlled trials of thyroxine replacement and clinical outcomes.36
Among the strengths of our study, an individual participant data analysis is the preferred
way to perform time-to-event analyses to avoid biases associated with the use of aggregate
data in meta-regression for subgroup analysis and to allow standardization of definitions of
predictors, outcomes, and adjustment for potential confounders.14,22 We included all
available international and published data on these associations. Among the limitations of
our study, the individual participant data analysis included predominantly white populations,
except for 2 studies conducted in Japan34 and Brazil.35 Results for subgroups at risk of CHD
mortality generally had wider 95% CIs than those for CHD events, reflecting less statistical
power. However, post hoc calculations showed 80% power to detect meaningful differences
between overall subclinical hypothyroidism and euthyroidism groups for each outcome.
Specifically, our study had adequate power to detect an HR of 1.18 or higher for CHD
events, an HR of 1.30 or higher for CHD mortality, and an HR of 1.13 or higher for total
mortality. Even with this very large amount of individual participant data, our power for
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subgroup analyses was limited among those with TSH levels of 10 mIU/L or greater or
adults younger than 50 years because of the limited number of CHD events and deaths.
Thyroid function testing was performed only at baseline, and we have no data on how many
participants progressed from euthyroidism to subclinical hypothyroidism, from subclinical
to overt hypothyroidism, or who normalized their TSH level over time, which is a limitation
of all published large cohorts.6,7,33 In addition, free triiodothyronine (T3) was not available
in most cohorts, and thus could not be included in thyroid status classification.
Commencement of thyroid medication during follow-up by up to 12.6% of participants
might have attenuated any true effects of subclinical hypothyroidism, as illustrated by the
sensitivity analysis excluding such participants.
In summary, combining all available data from large prospective cohorts among 55 287
individual participants suggests that subclinical hypothyroidism is associated with an
increased risk of CHD in those with higher TSH levels. The risk of both CHD mortality and
CHD events, but not of total mortality, increases with higher concentrations of TSH and is
significantly elevated in adults with TSH levels of 10 mIU/L or greater. Conversely,
minimal TSH elevations are not associated with an increased risk of CHD events and CHD
mortality. Our finding of no increased risk of CHD among the high proportions of adults
with minimal TSH elevations is also important because many patients with minimal TSH
elevations are currently treated in clinical practice.44 Our results might help refine a TSH
threshold at which larger clinical benefits of thyroxine replacement would be expected.4,45
Our study cannot address whether these risks are attenuated or abolished by thyroxine
replacement. Given the high prevalence of subclinical hypothyroidism,2,19 this question
needs to be addressed in an appropriately powered randomized controlled trial.
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Figure 1. Subclinical Hypothyroidism vs Euthyroidism for Coronary Heart Disease (CHD)
Events, CHD Mortality, and Total Mortalitya
aThe sizes of the data markers are proportional to the inverse variance of the hazard ratios
(HRs). CI indicates confidence interval; HUNT, Nord-Trøndelag Health Study; HR, hazard
ratio.
bForty-six participants from the Whickham survey and 3 participants from the Busselton
Health Study were not included because follow-up data were only available for death.
cNine participants were excluded from the analysis because of missing cause of death. The
Brazilian Thyroid Study was not included in this analysis because of unreliable estimates
based on the small number of CHD deaths (n=10).
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Figure 2. Hazard Ratios (HRs) for Coronary Heart Disease (CHD) Events, CHD Mortality, and
Total Mortality According to Elevated Thyroid-Stimulating Hormone (TSH) Categories and
Subclinical Hypothyroidism Stratified by Age vs Euthyroidisma
aThe sizes of the filled square data markers are proportional to the inverse variance of the
HRs. The unfilled squares indicate the reference categories. For the analyses stratified by
age, the HRs for CHD events, CHD mortality, and total mortality were adjusted for sex and
age as a continuous variable to avoid residual confounding within age strata. CI indicates
confidence interval.
bData were available from 7 studies.
cData were available from 10 studies. The Brazilian Thyroid Study was not included
because of unreliable estimates based on the small number of CHD deaths (n=10). Nine
participants were excluded from the analysis because of missing cause of death.
dData were available from 11 studies.
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